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YEAR IN CARDIOLOGY SERIESRYEAR IN CARDIOLOGY SERIES1721Year in Cardiac ImagingRaymond J. Gibbons, Philip A. Araoz, Eric E. Williamson
Gibbons and colleagues highlight the recent literature regarding single-photon emission
computed tomography, myocardial perfusion imaging, cardiac positron emission tomography,
cardiac computed tomography, and cardiac magnetic resonance imaging. The papers are
divided into the following sections: technical, patient safety, diagnosis, prognosis, structure
and function, and appropriateness. The authors stress that an integrated, multimodality
imaging approach is optimal for the solution of clinical problems.CLINICAL RESEARCH CARDIOVASCULAR RISK
1735egional LV Myocardial Dysfunction on CMR Imaging
Predicts Subsequent Cardiovascular EventsRaymond T. Yan, David Bluemke, Antoinette Gomes, Gregory Burke, Steve Shea, Kiang Liu,
Hossein Bahrami, Shantanu Sinha, Colin Wu, Veronica Fernandes, Robyn McClelland, João A. C. Lima
Yan and colleagues reviewed data collected during the MESA (Multi-Ethnic Study of
Atherosclerosis) to study the prognostic significance of left ventricular (LV) regional
myocardial dysfunction (RMD) in asymptomatic subjects without known coronary disease.
Participants underwent magnetic resonance imaging where RMD was defined as segmental
systolic wall thickening less than the 10th percentile of segment-specific normative data.
RMD was found in 26% of subjects. Heart failure developed in 1.0% of subjects without
RMD and in 2.6% of those with RMD. RMD was also predictive of several other hard
coronary events. RMD is an independent predictor beyond traditional risk factors and global
LV assessment for cardiovascular events.(continued on page A-23)
APRIL 26, 2011 (continued) A-23HEART RHYTHM DISORDERS1745Pericardial Fat Is Associated With the Presence and Severity of AFChristopher X. Wong, Hany S. Abed, Payman Molaee, Adam J. Nelson, Anthony G. Brooks,
Gautam Sharma, Darryl P. Leong, Dennis H. Lau, Melissa E. Middeldorp, Kurt C. Roberts-Thomson,
Gary A. Wittert, Walter P. Abhayaratna, Stephen G. Worthley, Prashanthan Sanders
Pericardial fat has been hypothesized to exert local pathogenic effects on nearby cardiac
structures. Wong and colleagues studied 110 patients undergoing atrial fibrillation (AF)
ablation and 20 control subjects with cardiac magnetic resonance imaging. Pericardial fat
volumes were significantly associated with the presence of AF, AF chronicity, and AF
symptom burden. Pericardial fat depots were also predictive of long-term AF recurrence
following ablation. These associations persisted after multivariable adjustment including body
weight. These findings are consistent with the hypothesis of a local pathogenic effect of
pericardial fat supporting AF.CARDIAC BIOMARKERS1752The Relationship Between Neutrophil Gelatinase-Associated Lipocalin Levels and AKIMichael Haase, Prasad Devarajan, Anja Haase-Fielitz, Rinaldo Bellomo, Dinna N. Cruz,
Gebhard Wagener, Catherine D. Krawczeski, Jay L. Koyner, Patrick Murray, Michael Zappitelli,
Stuart L. Goldstein, Konstantinos Makris, Claudio Ronco, Johan Martensson, Claes-Roland Martling,
Per Venge, Edward Siew, Lorraine B. Ware, T. Alp Ikizler, Peter R. Mertens
Neutrophil gelatinase-associated lipocalin (NGAL) detects acute kidney injury (AKI) prior to
increases in serum creatinine. Haase and colleagues pooled data from 10 studies to test the
hypothesis that increased NGAL levels identify AKI patients with worse prognosis. The
lowest risk of subsequent renal replacement therapy was in subjects with normal levels of both
NGAL and serum creatinine; the risk was higher in those with elevated NGAL but normal
creatinine, and highest in those with elevations in both markers. There were similar increases
in risk for hospital mortality and median number of intensive care days. Elevations in NGAL
identify patients with subclinical AKI who have an increased risk of adverse outcomes.
Editorial Comment: Peter A. McCullough, Mohamed El-Ghoroury, Hiroshi Yamasaki, p. 1762(continued on page A-24)
APRIL 26, 2011 (continued) A-24FROM AROUND THE WORLDNFOCUS ON INDIA1765Rapid Rise in Cardiac Risk Factors Among Young IndiansMark D. Huffman, Dorairaj Prabhakaran, Clive Osmond, Caroline H. D. Fall, Nikhil Tandon,
Ramakrishnan Lakshmy, Siddharth Ramji, Anita Khalil, Tarun Gera, Poornima Prabhakaran,
S. K. Dey Biswas, K. Srinath Reddy, Santosh K. Bhargava, Harshpal S. Sachdev, on behalf of the
New Delhi Birth Cohort
Huffman and colleagues analyzed data from the New Delhi Birth Cohort to track the
evolution of several cardiovascular disease (CVD) risk factors in a young urban Indian
population. A total of 1,100 participants were interviewed from 1998 to 2002, when the
mean age was 29 years, and then again 7 years later. The incidence of obesity increased by
approximately 2% per year. The prevalence of hypertension tripled from 11% to 34% in men
and 5% to 15% in women. Prevalence rates of diabetes doubled in both sexes. These results
suggest that young, urban Indians have a high risk of future CVD events.Editorial Comment: Gilles Paradis, Arnaud Chiolero, p. 1775EXPEDITED PUBLICATION EXPEDITED PUBLICATION
1778ew Zotarolimus-Eluting Coronary Stent Has Low Rates of Restenosis
and ThrombosisAlan C. Yeung, Martin B. Leon, Ash Jain, Thaddeus R. Tolleson, Douglas J. Spriggs, Brent T. Mc Laurin,
Jeffrey J. Popma, Peter J. Fitzgerald, Donald E. Cutlip, Joseph M. Massaro, Laura Mauri, on behalf of the
RESOLUTE US Investigators
The Resolute zotarolimus-eluting coronary stent (R-ZES) (Medtronic, Santa Rosa,
California) uses the same cobalt chromium stent platform and drug as the Endeavor-
zotarolimus-eluting coronary stent (E-ZES) (Medtronic), but utilizes a new polymer that
results in a longer duration of drug elution. The RESOLUTE US trial recruited patients
with de novo native coronary lesions who all received an R-ZES and were then compared
with historical patients who had received an E-ZES. In the main analysis cohort, target
lesion failure was 3.7% at 12 months for R-ZES compared with a historical E-ZES rate of
6.5%. The 12-month rate of stent thrombosis was 0.1% and occurred only in patients who
received a 2.25-mm stent. These results suggest that R-ZES may be both safer and more
efficacious than E-ZES.
